Chengdian (Suzhou) Biopharmaceutical Co. Ltd. has received IND clearance from the FDA, allowing it to initiate a first-in-human phase I trial of CD-001.
CDR-Life Inc. has reported preclinical data for the CDR-813, a novel antibody fragment-based bivalent T-cell engager targeting preferentially expressed antigen in melanoma (PRAME) on HLA-A*02:01.
Rakuten Medical Inc. has presented preclinical results with RM-0256, a PD-L1-targeted photoimmunotherapy, showing its ability to kill immunosuppressive myeloid cells to activate local and systemic antitumor immunity.
Australia is the skin cancer capital of the world, but with a shortage of dermatologists, patients often wait too long to get skin checks that could end up costing them their lives.
Guangdong HEC Pharmaceutical Co. Ltd. has described programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) interaction inhibitors reported to be useful for the treatment of cancer, infections and autoimmune disease.
Scientists at Centre National de la Recherche Scientifique, Ecole Nationale Supérieure de Chimie de Paris, Universitat de Barcelona and Université Paris Sciences et Lettres have divulged metal complexes (particularly Ru[II]) acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of cancer, dermatological disorders and fungal infections.
A paper from Shenzhen University and affiliated organizations covers the discovery of a novel bromodomain-containing protein 4 (BRD4)-specific proteolysis-targeting chimera (PROTAC).
Scientists and doctors are getting much better at developing treatments for cancer. More than 18 million people with a history of cancer were alive in the U.S. at the beginning of 2022, up from just 3 million in 1971, according to the 14th edition of the American Association for Cancer Research (AACR) Cancer Progress Report. And that number is expected to rise to 26 million by 2040.
RSS
